
369: Trump, Chinese biotech, and an industry career reshaped by illness
The Readout Loud
00:00
Ivanesimab: A Game Changer in Cancer Treatment?
This chapter explores the dual PD-1 VEGF inhibitor Ivanesimab, assessing its potential to surpass Merck's Keytruda in efficacy based on clinical trial data from China. It also discusses the implications of Western patient demographics on the drug's success and highlights recent developments at Novo Nordisk amid industry shifts.
Transcript
Play full episode